Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02156674 · ClinicalTrials.gov registry record · NA
Naglazyme After Allo Transplant for Maroteaux-Lamy Syndrome
A NA study, sponsored by Masonic Cancer Center, University of Minnesota.
- Terminated
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT02156674 is a NA study that was terminated before completion, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 1 participants.
The verdict
NCT02156674, a NA study, was terminated before completion, sponsored by Masonic Cancer Center, University of Minnesota.
- TERMINATED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is a single center study in which Naglazyme® will be given weekly for two years in patients with Maroteaux-Lamy syndrome, also known as mucopolysaccharide VI (MPS VI), who have previously been treated with an allogeneic transplant.
Interventions
- DRUG Naglazyme®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2016-01-26 |
| Est. Completion | 2019-12-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02156674
The ClinicalTrials.gov registry entry for NCT02156674 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Naglazyme® is the first listed.
NCT02156674 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02156674 about?
NCT02156674 is a clinical study titled "Naglazyme After Allo Transplant for Maroteaux-Lamy Syndrome". This is a single center study in which Naglazyme® will be given weekly for two years in patients with Maroteaux-Lamy syndrome, also known as mucopolysaccharide VI (MPS VI), who have previously been treated with an allogeneic transplant.
What is the current status of trial NCT02156674?
This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2016-01-26. Estimated completion is 2019-12-01.
What interventions are being tested in trial NCT02156674?
The interventions under investigation include: Naglazyme® (DRUG).
Who is sponsoring clinical trial NCT02156674?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.